Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueEquity AverageEquity RatioInterest Coverage RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on EquityTimes Interest Earned

Corbus Pharmaceuticals Holdings (CRBP) Equity Average (2016 - 2025)

Corbus Pharmaceuticals Holdings has reported Equity Average over the past 9 years, most recently at -$3.3 million for Q4 2023.

  • For Q4 2023, Equity Average fell 108.8% year-over-year to -$3.3 million; the TTM value through Dec 2023 reached -$3.3 million, down 108.8%, while the annual FY2023 figure was $13.0 million, 74.45% down from the prior year.
  • Equity Average for Q4 2023 was -$3.3 million at Corbus Pharmaceuticals Holdings, down from $4.9 million in the prior quarter.
  • Over five years, Equity Average peaked at $84.2 million in Q2 2021 and troughed at -$3.3 million in Q4 2023.
  • A 5-year average of $40.4 million and a median of $38.0 million in 2019 define the central range for Equity Average.
  • Biggest five-year swings in Equity Average: surged 374.16% in 2021 and later crashed 108.8% in 2023.
  • Year by year, Equity Average stood at $17.9 million in 2019, then surged by 108.11% to $37.3 million in 2020, then soared by 96.96% to $73.4 million in 2021, then crashed by 48.93% to $37.5 million in 2022, then tumbled by 108.8% to -$3.3 million in 2023.
  • Business Quant data shows Equity Average for CRBP at -$3.3 million in Q4 2023, $4.9 million in Q3 2023, and $13.0 million in Q2 2023.